Press "Enter" to skip to content

Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma – BioSpace

admin 0

Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma  BioSpace

NEW YORK–(BUSINESS WIRE)– Tiziana Life Sciences Plc (NASDAQ: TLSA), a biotechnology company focusing on the discovery and development of …

“liver cancer” – Google News

(Visited 4 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *